Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

European CPMP issues positive opinion for oxybutynin transdermal patch

Nov. 26, 2003

New muscarinic M3 antagonists and their use in urinary incontinence, COPD, IBS, etc.

Nov. 25, 2003

Lilly Icos receives FDA approval for Cialis

Nov. 25, 2003

GPI-1485 enters phase II trial for postprostatectomy erectile dysfunction

Nov. 20, 2003

HCT-1026 and ibuprofen reduce resiniferatoxin-induced bladder hyperactivity in rats

Nov. 19, 2003

Therapeutic benefits of intraurethral botulinum toxin type A in urinary tract dysfunction

Nov. 17, 2003

New uroselective alpha1-AR antagonists developed at Ranbaxy

Nov. 14, 2003

Sumitomo claims TGF-beta antagonists with potential in fibrotic disorders

Nov. 10, 2003

New NK1 antagonists identified by Kyorin researchers

Nov. 10, 2003

Nippon Shinyaku grants Apogepha European rights for NS-8

Nov. 7, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...